Fox Chase Cancer Center News

PHILADELPHIA (July 23, 2021) – The percentage of inflammatory breast cancer (IBC) patients selecting reconstructive surgery after mastectomy, whether immediate or delayed, remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research.

PHILADELPHIA (July 23, 2021)—Researchers at Fox Chase Cancer Center recently conducted a mouse model study showing that tumor size can be reduced in cases of neurofibromatosis type 2 (NF2) by targeting PAK1, a gene that regulates cell motility and morphology. PAKs are members of the p21-activated kinase family represented by six genes (PAK1-6).

PHILADELPHIA (July 23, 2021)—Over 90% of head and neck cancer patients found weekly palliative care visits to be a valuable addition to their treatment, a recent study conducted at Fox Chase Cancer Center has concluded.

PHILADELPHIA (July 23, 2021) – Although it improved certain aspects of adaptive coping among prostate cancer survivors, a small randomized, controlled trial found use of PROGRESS, a web-based intervention developed at Fox Chase Cancer Center, did not fully address coping and psychosocial demands. 

PHILADELPHIA (July 23, 2021)—Fox Chase Cancer Center recently awarded grants to two fellows to continue work on projects related to patient care in their fields. These funds were raised as part of Fox Chase’s annual In Vino Vita Benefit and Wine Auction.

PHILADELPHIA (July 22, 2021)—In a study published today in JAMA Oncology, researchers at Fox Chase Cancer Center found that the odds of a patient undergoing prostate cancer surgery were lower among Black patients compared with white patients during the initial wave of the COVID-19 pandemic.

PHILADELPHIA (July 22, 2021)—Charline Ogier, PhD, a postdoctoral researcher at Fox Chase Cancer Center, was recently awarded a fellowship from the Pancreatic Cancer Action Network (PanCAN) to continue her work in advancing pancreatic cancer therapies.

PHILADELPHIA (July 22, 2021)—Ralph Francescone, PhD, a researcher at Fox Chase Cancer Center, was recently awarded a grant from the Pancreatic Cancer Action Network (PanCAN) to continue his work in advancing pancreatic cancer therapies.